Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Proton who wrote (17777)	3/21/1998 5:25:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 32384

Peter, no, they did not provide the full data. I left the article at work, so I don't even have the partial data: one can assume most of the tombstones going to zero, but there are a few complicated cases for which it would be hard to trace back the actual return, such as the Hybritech takeover by Lilly. The comparison you propose would indeed be quite interesting. It may be possible to do it for the last 5 or 10 years; probably not pretty for the biotechs. One caveat on the DRG vs BTK game is that the former is likely to remain quite stable (ignoring merger mania for the moment), while the latter is likely to have some future tombstones right now. So, your emphasis on current components , for the forward comparison, is important to note and take into account. PB

To: Proton who wrote (17777)	3/22/1998 5:05:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 32384

Peter, here is the entire list. Order is company, label, what $100 worth of its stock in July 83 would be worth today (when the issue went to press, actually), if applicable; plus some comments in a few cases. Enjoy, Amgen Medal(M) $4900 BioLogicals Tombstone (TS) Bio-Response (TS) Biogen (M) $270 Biotech Research Labs (TS) Biotechnica Intl. (TS) Cambridge BioScience Turtle (T), became Aquila in 1996 Centocor (M) $440 Cetus (TS) acquired by Chiron Collaborative Research (T) $65 - changed name to Genome Therapeutics (GENE) Damon Biotech (TS) Enzo Biochem (T) $91 Genentech Ring (R) $423 ("share value complicated because of Roche deal") Genetic Engineering (TS) Genetic Systems (R) Acquired by BMY in 1986 - would have made good money if bought at or after IPO Genex (TS) Hybritech (R) - bought by Lilly, then sold to Beckman Immunex (R) $425 Interferon Sciences (T) $25 Molecular Genetics (T) $25 now is MGI Pharm (MOGN) Monoclonal Antibodies (TS) Ribi Immunochem (T) $62 Summa Medical (TS) $0 "company stock still quoted at this price" (I have not double-checked this statement).